Cargando…
Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
Although evidence has accumulated that long-term aspirin therapy is beneficial in secondary prevention of cardiovascular disease (CVD), a lot of controversies persist regarding the benefit of aspirin use in primary prevention of CVD. In low-income countries (LIC) specifically, the decision to prescr...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556041/ https://www.ncbi.nlm.nih.gov/pubmed/26345154 http://dx.doi.org/10.2147/VHRM.S87398 |
_version_ | 1782388294059819008 |
---|---|
author | Noubiap, Jean Jacques N Nansseu, Jobert Richie N |
author_facet | Noubiap, Jean Jacques N Nansseu, Jobert Richie N |
author_sort | Noubiap, Jean Jacques N |
collection | PubMed |
description | Although evidence has accumulated that long-term aspirin therapy is beneficial in secondary prevention of cardiovascular disease (CVD), a lot of controversies persist regarding the benefit of aspirin use in primary prevention of CVD. In low-income countries (LIC) specifically, the decision to prescribe aspirin for primary CVD prevention is more problematic, as there is a dearth of evidence in this regard. Aspirin has been shown to have relative beneficial effects in preventing a first myocardial infarction, but not stroke. However, as stroke is the prevailing CVD in many LIC, especially in Africa, the benefit of aspirin in these settings is therefore questionable. Indeed, there is no published trial that has evaluated the benefits and risks of continuous aspirin therapy in populations of LIC. Furthermore, though cardiovascular risk assessment is crucial in decision-making for the use of aspirin in primary prevention of CVD, there are no risk assessment tools that have been validated in African populations. Studies are urgently warranted, to determine the usefulness of aspirin in primary prevention of CVD in low-income settings where the drug is highly available and affordable, as CVD is becoming the leading cause of deaths in LIC. |
format | Online Article Text |
id | pubmed-4556041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45560412015-09-04 Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? Noubiap, Jean Jacques N Nansseu, Jobert Richie N Vasc Health Risk Manag Commentary Although evidence has accumulated that long-term aspirin therapy is beneficial in secondary prevention of cardiovascular disease (CVD), a lot of controversies persist regarding the benefit of aspirin use in primary prevention of CVD. In low-income countries (LIC) specifically, the decision to prescribe aspirin for primary CVD prevention is more problematic, as there is a dearth of evidence in this regard. Aspirin has been shown to have relative beneficial effects in preventing a first myocardial infarction, but not stroke. However, as stroke is the prevailing CVD in many LIC, especially in Africa, the benefit of aspirin in these settings is therefore questionable. Indeed, there is no published trial that has evaluated the benefits and risks of continuous aspirin therapy in populations of LIC. Furthermore, though cardiovascular risk assessment is crucial in decision-making for the use of aspirin in primary prevention of CVD, there are no risk assessment tools that have been validated in African populations. Studies are urgently warranted, to determine the usefulness of aspirin in primary prevention of CVD in low-income settings where the drug is highly available and affordable, as CVD is becoming the leading cause of deaths in LIC. Dove Medical Press 2015-08-25 /pmc/articles/PMC4556041/ /pubmed/26345154 http://dx.doi.org/10.2147/VHRM.S87398 Text en © 2015 Noubiap and Nansseu. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Commentary Noubiap, Jean Jacques N Nansseu, Jobert Richie N Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? |
title | Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? |
title_full | Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? |
title_fullStr | Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? |
title_full_unstemmed | Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? |
title_short | Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? |
title_sort | are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556041/ https://www.ncbi.nlm.nih.gov/pubmed/26345154 http://dx.doi.org/10.2147/VHRM.S87398 |
work_keys_str_mv | AT noubiapjeanjacquesn arethecurrentrecommendationsfortheuseofaspirininprimarypreventionofcardiovasculardiseaseapplicableinlowincomecountries AT nansseujobertrichien arethecurrentrecommendationsfortheuseofaspirininprimarypreventionofcardiovasculardiseaseapplicableinlowincomecountries |